菝葜活性成份对慢性盆腔炎大鼠子宫组织肿瘤坏死因子-ɑ和白介素-4的影响

Effect of Smilax china bioactive fraction on tumor necrosis factor-α and interleukin-4 contents in uterine tissue of rats with chronic pelvic inflammatory disease

目的探讨菝葜活性成份治疗慢性盆腔炎的作用机制。方法采用化学烧伤的方法建立慢性盆腔炎大鼠模型。对70只大鼠随机分为模型对照组,假手术组,空白对照组,菝葜活性成份高、中、低剂量组,金刚藤胶囊组。治疗14 d后,观察子宫肿胀率和抑制率,酶联免疫法检测各组大鼠子宫组织中TNF-α和IL-4的表达情况。结果光学显微镜下观察显示:菝葜活性成份高、中、低剂量组能降低大鼠子宫内膜的炎症细胞,促进其病变上皮细胞增生修复,减轻浆膜充血水肿。与模型对照组比较,菝葜活性成份高、中剂量组能降低慢性盆腔模型大鼠子宫的肿胀率(P<0.01);菝葜活性成份高、中、低剂量组子宫组织中TNF-α的含量明显降低(P<0.01);菝葜活性成份高、中剂量组子宫组织中IL-4的含量明显升高(P<0.01),菝葜活性成份低剂量组子宫组织中IL-4的含量升高(P<0.05)。结论菝葜活性成份能影响慢性盆腔炎大鼠子宫的肿胀率及子宫组织中TNF-α、IL-4的水平,这可能是菝葜活性成份治疗慢性盆腔炎症和缓解盆腔粘连的药理作用机制之一。

Objective To study the mechanism that mediates the therapeutic effect of the bioactive fraction of Baqia （Smilax china） on chronic pelvic inflammatory disease （CPID）. Methods Seventy rats were randomized into CPID model group, sham-operated group, normal control group, Jingangteng capsule group, and high-, medium-, and low-dose Baqia groups. Rat models of CPID were established by inducing chemical burns of the uterus and corresponding treatments were administered. After 14 days of treatment, the rat uterus was observed for swelling and inhibition rate, and the expressions of tumor necrosis factor-α（TNF-α） and interleukin-4 （IL-4） in the uterine tissues were determined using enzyme-linked immumsorbent assay. Results The bioactive fraction of Baqia at the 3 doses obviously reduced the inflammatory cells in the endometrium, promoted epithelial cell proliferation, and ameliorated congestion and edema of the serosa. High and medium doses of Baqia bioactive fraction significantly decreased uterus swelling rate of the rats （P＆lt;0.01）. All the 3 doses of the Baqia biaoactive fraction obviously decreased uterine TNF-αcontent （P＆lt;0.01） and significantly increased uterine IL-4 expression level （P＆lt;0.05）, and IL-4 up-regulation was especially obvious in high and medium dose groups （P＆lt;0.01）. Conclusion Baqia bioactive fraction can ameliorate uterine swelling, lower uterine TNF-α and increase IL-4 expressions in rats with CPID, which may be a pharmacological mechanism underlying its therapeutic effect on CPID and cervical adhesion.